Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Southern Cross Pharma Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (259)
Cancellation by sponsor (204)
Prescription medicine registration (22)
Australian public assessment report (AusPar) (4)
Prescription medicine decision summary (1)
Section 14, TGO91 consent (1)

Date

2025 (5)
2024 (16)
2023 (30)
2022 (102)
2021 (29)
2020 (50)
2019 (59)
2018 (35)
2017 (50)
2016 (22)
2015 (17)
2014 (9)
2013 (11)
2012 (19)
2011 (9)
2010 (10)
2009 (13)
2008 (3)
2007 (1)
2003 (1)

Search

Sponsor content

491 result(s) found, displaying 301 to 310

LABETALOL RMB, LABETALOL SXP, LABETALOL TLB (Southern Cross Pharma Pty Ltd)

23 August 2019

Prescription medicine registration

Active ingredients: labetalol hydrochloride.
APO-CLONIDINE clonidine hydrochloride 100 micrograms tablet bottle (265776)

24 November 2016

ARTG

Australian Register of Therapeutic Goods (ARTG) information for APO-CLONIDINE clonidine hydrochloride 100 micrograms tablet bottle.
CLONIDINE Lupin clonidine hydrochloride 100 micrograms tablet bottle (265778)

24 November 2016

ARTG

Australian Register of Therapeutic Goods (ARTG) information for CLONIDINE Lupin clonidine hydrochloride 100 micrograms tablet bottle.
CLONIDINE SCP clonidine hydrochloride 100 micrograms tablet bottle (265777)

24 November 2016

ARTG

Australian Register of Therapeutic Goods (ARTG) information for CLONIDINE SCP clonidine hydrochloride 100 micrograms tablet bottle.
PHARMACOR AMISULPRIDE amisulpride 200 mg uncoated tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
PHARMACOR AMISULPRIDE amisulpride 400 mg uncoated tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
PHARMACOR AMISULPRIDE amisulpride 100 mg uncoated tablet blister pack Cancelled under Section 30(1)(c) of the Act

28 June 2019

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
TEMOLIDE temozolomide 20mg capsule bottle Cancelled under Section 30(1)(c) of the Act

25 June 2019

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
TEMOLIDE temozolomide 250 mg capsule bottle Cancelled under Section 30(1)(c) of the Act

25 June 2019

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd
TEMOLIDE temozolomide 100 mg capsule bottle Cancelled under Section 30(1)(c) of the Act

25 June 2019

Cancellation by sponsor

Requested by Southern Cross Pharma Pty Ltd

Pages

First page
Previous page
…
Page 27
Page 28
Page 29
Page 30
Current page 31
Page 32
Page 33
Page 34
Page 35
…
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.